Metformin upregulates hENT1 expression and enhances gemcitabine efficacy in pancreatic cancer cells

被引：2
|
作者：
Joseph, Stancy J. [1 ]
Osborne, Taylor [1 ]
Word, Beverly [1 ]
Lyn-Cook, Beverly [1 ]
机构：
[1] US FDA, NCTR, Jefferson, AR USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-4436
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4436
引用
收藏
页数：1
相关论文
共 50 条
  • [41] WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition
    Wang, Ruquan
    Li, Yongliang
    Gao, Jianjun
    Luan, Yepeng
    DRUG DISCOVERIES AND THERAPEUTICS, 2022, 16 (06): : 286 - 292
  • [42] Can hENT1 Expression in EUS-FNAB Samples be the Prognostic Factor of Pancreatic Ductal Adenocarcinoma Before Gemcitabine-based Chemoradiotherapy?
    Yamada, R.
    Mizuno, S.
    Inoue, H.
    Murata, Y.
    Kuriyama, N.
    Azumi, Y.
    Kishiwada, M.
    Usui, M.
    Sakurai, Y.
    Isaji, S.
    PANCREAS, 2014, 43 (08) : 1425 - 1425
  • [43] Comparative Study of hENT1 Expression in Pancreatic Cancer; EUS-FNB Samples Before Gemcitabine-Based Chemoradiatherapy Versus Resected Specimens After Chemoradiotherapy
    Yamada, R.
    Isaji, S.
    Murata, Y.
    PANCREAS, 2012, 41 (07) : 1155 - 1156
  • [44] Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells
    Ahn, Hye-Mi
    Kim, Dong-Gun
    Kim, Youn-Jae
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 527 (02) : 568 - 573
  • [45] SPARC expression enhances cellular aggregation and resistance to gemcitabine in pancreatic cancer cells
    Salvatierra, Edgardo
    Rivas, Elvia
    Guttlein, Leandro
    Robitschek, Emily
    Llera, Andrea
    Podhajcer, Osvaldo
    CANCER RESEARCH, 2015, 75
  • [46] Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer
    Li, Jie
    Wang, Ruixin
    Schweickert, Patrick G.
    Karki, Anju
    Yang, Yi
    Kong, Yifan
    Ahmad, Nihal
    Konieczny, Stephen F.
    Liu, Xiaoqi
    CELL CYCLE, 2016, 15 (05) : 711 - 719
  • [47] EXPRESSION OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (HENT1) IS A NOVEL PROGNOSIC MARKER IN ADVANCED BLADDER CANCER PATIENTS WITH GEMCITABINE-BASED CHEMOTHERAPY
    Matsumura, Nagahide
    Nakamura, Yasushi
    Nanpo, Yoshihito
    Kodama, Yoshiki
    Kikkawa, Kazuro
    Ura, Kuniyoshi
    Kusumoto, Hiroki
    Inagaki, Takeshi
    Kohjimoto, Yasuo
    Hara, Isao
    JOURNAL OF UROLOGY, 2011, 185 (04): : E795 - E795
  • [48] DPD and hENT1 are Not Predictive in Patients with Resected Pancreatic Cancer Treated with Adjuvant S-1 or Gemcitabine Chemotherapy: Collaborative Study of the JASPAC 01 Trial
    Okamura, Y.
    Yasukawa, S.
    Mori, K.
    Boku, N.
    Akira, F.
    Konishi, M.
    Morinaga, S.
    Toyama, H.
    Kaneoka, Y.
    Shimizu, Y.
    Nakamori, S.
    Sata, N.
    Kainuma, O.
    Kitano, Y.
    Sakamoto, H.
    Yamaguchi, R.
    Hishinuma, S.
    Hirano, S.
    Yanagisawa, A.
    Uesaka, K.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S134 - S134
  • [49] Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer
    Deng, Ting
    Pan, Hong
    Han, Rubing
    Huang, Dingzhi
    Li, Hongli
    Zhou, Likun
    Wang, Xia
    Bai, Ming
    Li, Xiang
    Liu, Rui
    Ge, Shaohua
    Ning, Tao
    Zhang, Le
    Ba, Yi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 7 (12): : 5041 - 5049
  • [50] Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy
    Soichiro Morinaga
    Yoshiyasu Nakamura
    Takuo Watanabe
    Hiroshi Mikayama
    Hiroshi Tamagawa
    Naoto Yamamoto
    Manabu Shiozawa
    Makoto Akaike
    Shinnichi Ohkawa
    Yoichi Kameda
    Yohei Miyagi
    Annals of Surgical Oncology, 2012, 19 : 558 - 564
12345